Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Non-Small Cell Lung Cancer
Title   A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (Cypress 2)
Summary   The purpose of this research study is to measure how well and how safe AM0010 in combination with nivolumab is in treating patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have low PD-L1 expression.
Description   Patients will randomly be placed into one of two groups. Both groups will receive nivolumab once every two weeks, but only one group will receive the study drug AM0010. This group will self-administer this injection daily.
IRB Number   18007
Inclusion/Notes   To be eligible for this study patients must meet several criteria, including but not limited to the following: confirmed Stage IV/metastatic or recurrent wild type non-small cell lung cancer (NSCLC), have received at least one prior systemic therapy that was not an anti-PD-1, anti-PD1-L1 and/or anti-CTLA-4 treatment, patients with tumor tissue low expression of PD-L1 0%-49%
Status   Open
Start Date   12/26/2017
Principal Name   Jeffery Schneider, MD
Contact Name   Jena Trebendis, RN
Email   Jena.Trebendis@nyulangone.org
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-1811
Alternate Phone   516-663-3115